Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment.

Adrien KrugMarie TosoliniBlandine Madji HounoumJean-Jacques FourniéRoger GeigerMatteo PecoraroPatrick EmondPhilippe GaulardFrançois LemonnierJean-Ehrland RicciEls Verhoeyen

Published in: Journal of experimental & clinical cancer research : CR (2024)

Our results suggest that interfering with choline metabolism in AITL reveals a specific metabolic vulnerability and might represent a new therapeutic strategy for these patients.

Keyphrases

climate change
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
bone marrow
patient reported outcomes
combination therapy
patient reported